                         SEQUENCE LISTING

<110>  Washington University
 
<120>  METHODS AND COMPOSITIONS FOR IMAGING AND TREATING CANCER

<130>  019463/WO

<150>  63/088,062
<151>  2020-10-06

<160>  30    

<170>  PatentIn version 3.5

<210>  1
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  1

Thr Phe Leu Lys Cys 
1               5   


<210>  2
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa in position 1 is absent, is glycine or represents an amino 
       acid sequence selected from the group consisting of LG, YLG, and 
       HYLG.

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa in position 7 independently is absent, is methionine, or 
       represents an amino acid sequence selected from the group 
       consisting of MA, MAN, MANG, MANGF, MANGFV, MANGFVW, MANGFVWE, 
       and MANGFVWEN

<400>  2

Xaa Thr Phe Leu Lys Cys Xaa 
1               5           


<210>  3
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ECL1 (C) inverso; ECL1i

<400>  3

Leu Gly Thr Phe Leu Lys Cys 
1               5           


<210>  4
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  4

His Tyr Leu Gly Thr Phe Leu Lys Cys Met Ala 
1               5                   10      


<210>  5
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  5

Leu Gly Thr Phe Leu Lys Cys Met Ala 
1               5                   


<210>  6
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  6

His Tyr Leu Gly Thr Phe Leu Lys Cys 
1               5                   


<210>  7
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  7

Gly Thr Phe Leu Lys Cys Met Ala Asn Gly Phe 
1               5                   10      


<210>  8
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  8

Thr Phe Leu Lys Cys Met Ala Asn Gly Phe Val 
1               5                   10      


<210>  9
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  9

His Tyr Leu Gly Thr Phe Leu Lys Cys Met Ala Asn Gly Phe Val Trp 
1               5                   10                  15      


<210>  10
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ECL1 (C)

<400>  10

Cys Lys Leu Phe Thr Gly Leu 
1               5           


<210>  11
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ECL2 (N)

<400>  11

Leu Phe Thr Lys Cys 
1               5   


<210>  12
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ECL2 (N) inverso

<400>  12

Cys Lys Thr Phe Leu 
1               5   


<210>  13
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ECL3 (C)

<400>  13

His Thr Leu Met Arg Asn Leu 
1               5           


<210>  14
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ECL3 (C) inverso

<400>  14

Leu Asn Arg Met Leu Thr His 
1               5           


<210>  15
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ECL3 (N)

<400>  15

Leu Asn Thr Phe Gln Glu Phe 
1               5           


<210>  16
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ECL3 (N) inverso

<400>  16

Phe Glu Gln Phe Thr Asn Leu 
1               5           


<210>  17
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  17

Thr Phe Leu Lys 
1               


<210>  18
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa in position 1 is absent, is glycine or represents an amino 
       acid sequence selected from the group consisting of AG, LG, YLG, 
       and HYLG.

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa in position 6 independently is absent or is alanine.

<400>  18

Xaa Thr Phe Leu Lys Xaa 
1               5       


<210>  19
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  19

Leu Gly Thr Phe Leu Lys 
1               5       


<210>  20
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  20

Ala Gly Thr Phe Leu Lys Cys 
1               5           


<210>  21
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  21

Leu Gly Thr Phe Leu Lys Ala 
1               5           


<210>  22
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  22

Gly Thr Phe Leu Lys 
1               5   


<210>  23
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  23

Ala Gly Thr Phe Leu Lys Ala 
1               5           


<210>  24
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  24

Met Ala Asn Gly 
1               


<210>  25
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  25

Met Ala Asn Gly Phe 
1               5   


<210>  26
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  26

Met Ala Asn Gly Phe Val 
1               5       


<210>  27
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  27

Met Ala Asn Gly Phe Val Trp 
1               5           


<210>  28
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  28

Met Ala Asn Gly Phe Val Trp Glu 
1               5               


<210>  29
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  29

Met Ala Asn Gly Phe Val Trp Glu Asn 
1               5                   


<210>  30
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CCR2 binding peptide

<400>  30

His Tyr Leu Gly 
1               


